首页> 外文期刊>Bone marrow transplantation >Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data
【24h】

Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data

机译:急性髓性白血病老年患者的异化造血细胞移植的长期结果:10年后续数据的回顾性分析

获取原文
获取原文并翻译 | 示例
       

摘要

The long-term outcomes of allogeneic hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC) remain inconclusive. To address this issue, we conducted a nationwide registry-based study of patients with acute myeloid leukemia (AML) age 50 years or older who underwent allogeneic HCT in complete remission using RIC (n = 284) or myeloablative conditioning (MAC, n = 190) between 2002 and 2007. The median follow-up period for surviving patients was 10.1 years for RIC recipients and 10.4 years for MAC recipients. The 10-year probabilities of overall survival, relapse, and non-relapse mortality were 36.4%, 30.0%, and 35.7% for RIC recipients, and 39.8%, 26.3%, and 35.5% for MAC recipients, respectively. Multivariate analysis revealed that the conditioning intensity did not affect overall mortality (P = 0.184), relapse (P = 0.904), or non-relapse mortality (P = 0.387). For the 218 patients qualifying for propensity score-matched pairing (109 pairs), RIC was found to be associated with similar survival (P = 0.095) and relapse (P = 0.467), and significantly lower non-relapse mortality (P = 0.046) compared with MAC. Our results confirm the long-term efficacy of RIC allogeneic HCT for older patients with AML and mitigate concerns over an increase in late relapse.
机译:具有减少强度调理(RIC)的同种异体造血细胞移植(HCT)的长期结果仍然不确定。为了解决这个问题,我们在50岁或以上的急性髓性白血病(AML)的患者进行了基于急性髓性白血病(AML)的基于患者的基于患者的研究,该研究在使用RIC(n = 284)或髓鞘调节(MAC,N = 190 )2002年至2007年。幸存患者的中位随访期为RIC受者为10.1岁,Mac接受者10.4岁。 RIC受者的总体存活率,复发和非复发性死亡率的10年概率为36.4%,30.0%和35.7%,分别为39.8%,26.3%和35.5%。多变量分析表明,调节强度不影响总体死亡率(P = 0.184),复发(P = 0.904),或非复发死亡率(P = 0.387)。对于倾向分数配对(109对)的218名患者,发现RIC与类似的存活相关(P = 0.095)和复发(P = 0.467),并且显着降低了非复发性死亡率(P = 0.046)与Mac相比。我们的结果证实了RIC同种异体HCT对老年患者的长期疗效,并减轻了晚期复发增加的担忧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号